CHE vs. AMED, OPCH, VKTX, ROIV, EHC, HSIC, ASND, RGEN, LEGN, and CERE
Should you be buying Chemed stock or one of its competitors? The main competitors of Chemed include Amedisys (AMED), Option Care Health (OPCH), Viking Therapeutics (VKTX), Roivant Sciences (ROIV), Encompass Health (EHC), Henry Schein (HSIC), Ascendis Pharma A/S (ASND), Repligen (RGEN), Legend Biotech (LEGN), and Cerevel Therapeutics (CERE). These companies are all part of the "medical" sector.
Amedisys (NASDAQ:AMED) and Chemed (NYSE:CHE) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.
Chemed has a net margin of 12.36% compared to Chemed's net margin of -0.91%. Amedisys' return on equity of 30.52% beat Chemed's return on equity.
Chemed has higher revenue and earnings than Amedisys. Amedisys is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.
Amedisys has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Chemed has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500.
Amedisys currently has a consensus price target of $100.80, suggesting a potential upside of 7.14%. Chemed has a consensus price target of $681.00, suggesting a potential upside of 19.01%. Given Amedisys' stronger consensus rating and higher possible upside, analysts plainly believe Chemed is more favorable than Amedisys.
94.4% of Amedisys shares are held by institutional investors. Comparatively, 95.9% of Chemed shares are held by institutional investors. 1.8% of Amedisys shares are held by insiders. Comparatively, 3.3% of Chemed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Amedisys and Amedisys both had 6 articles in the media. Amedisys' average media sentiment score of 1.12 beat Chemed's score of 0.81 indicating that Chemed is being referred to more favorably in the news media.
Amedisys received 166 more outperform votes than Chemed when rated by MarketBeat users. However, 63.39% of users gave Chemed an outperform vote while only 58.93% of users gave Amedisys an outperform vote.
Summary
Chemed beats Amedisys on 15 of the 17 factors compared between the two stocks.
Get Chemed News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
